Novo Nordisk A/S Common Stock (NVO)
Stock · NYSE · Health Care
$45.6as of 8/28/2026
Price chart
Open in TradingViewActive signals
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare b…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 66,700
- Website
- www.novonordisk.com/
Fundamentals
- 1-day range
- $45.41$46.21
- Market cap
- $203.55B
- P/E (trailing)
- 11.40
- P/E (forward)
- 13.30
- EPS (trailing)
- $26.18
- Dividend yield
- 1.00%
- Beta
- 1.92
- Avg. volume
- 12.39M
- Ex-dividend date
- August 17, 2026
- Dividend pay date
- August 25, 2026
Forecasts
12 analyst ratings
Novo Nordisk A/S Common Stock Competitors
Chosen by industry and closest market cap.
- NVONovo Nordisk A/S Common Stock$45.6▼ 1.43%Market cap $203.55BP/E 11.40$224.25$409.95
- ABTAbbott Laboratories Common Stock$112.42▲ 0.74%Market cap $186.81BP/E 35.52$81.97$137.49
- AZNAstraZeneca PLC Ordinary Shares$162.69▼ 1.11%Market cap $249.78BP/E 23.44$10,784$15,730
- PFEPfizer Inc. Common Stock$27.95▼ 0.25%Market cap $149.33BP/E 35.19$23.58$28.75
- VRTXVertex Pharmaceuticals Incorporated Common Stock$541.72▼ 1.06%Market cap $122.68BP/E 30.70$374.17$555.69
- NVSNovartis AG Common Stock$153.79▼ 0.56%Market cap $294.26BP/E 21.95$96.03$131.5
- GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)$50.82▲ 1.09%Market cap $105.65BP/E 15.53$1,441$2,282
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NVO Novo Nordisk A/S Common Stock | $203.55B | 11.40 | $45.6 | ▼ 1.43% | $224.25$409.95 |
| ABT Abbott Laboratories Common Stock | $186.81B | 35.52 | $112.42 | ▲ 0.74% | $81.97$137.49 |
| AZN AstraZeneca PLC Ordinary Shares | $249.78B | 23.44 | $162.69 | ▼ 1.11% | $10,784$15,730 |
| PFE Pfizer Inc. Common Stock | $149.33B | 35.19 | $27.95 | ▼ 0.25% | $23.58$28.75 |
| VRTX Vertex Pharmaceuticals Incorporated Common Stock | $122.68B | 30.70 | $541.72 | ▼ 1.06% | $374.17$555.69 |
| NVS Novartis AG Common Stock | $294.26B | 21.95 | $153.79 | ▼ 0.56% | $96.03$131.5 |
| GSK GSK plc American Depositary Shares (Each representing two Ordinary Shares) | $105.65B | 15.53 | $50.82 | ▲ 1.09% | $1,441$2,282 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Biohaven: Buy Reiterated On Opakalim License Agreement For Epilepsy And MoreSeekingAlpha · 8/27/2026
- 10 Health Care Stocks With Whale Alerts In Today’s SessionBenzinga · 8/27/2026
- Boston Scientific Reports Global Disruption After Cybersecurity IncidentBenzinga · 8/26/2026
- Eli Lilly Announces Results From Real-World Study Of Overweight Or Obese Adults Over 55 Indicating That Staying On Zepbound For Weight Management Lowered Healthcare Costs Over TimeBenzinga · 8/26/2026
- Novo Nordisk: Don't Ignore This Dirt-Cheap Buying OpportunitySeekingAlpha · 8/24/2026
- Eli Lilly: Shaking Off Competition From The Dethroned Novo NordiskSeekingAlpha · 8/22/2026
- Novo Nordisk: The Pill That Could Close The Gap With LillySeekingAlpha · 8/21/2026
- 10 Health Care Stocks Whale Activity In Today’s SessionBenzinga · 8/21/2026
- 4 Health Care Stocks With Whale Alerts In Today’s Sessionbenzinga · 8/17/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 403.38M
- Total value held
- $14.15B
- Institutional holders
- 1272
- Unknown31.02M
- Unknown20.14M
- Unknown19.33M
- Unknown17.02M
- Unknown16.08M
- Unknown12.88M
- Unknown11.80M
- Unknown11.06M
- Unknown10.87M
- Unknown10.77M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedSynthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
August 30, 2026
Novo Nordisk Draws Renewed Attention After Two Recent Analyst Notes. Two analyst notes on Novo Nordisk were published over the past week. One commentator described the stock as a "dirt-cheap buying opportunity," citing valuation as a key point. Separately, a separate article highlighted significant whale-alert trading activity in today's session, indicating large institutional moves in the name. Taken together, the coverage reflects renewed market focus on Novo Nordisk, though the articles do not agree on whether recent price weakness reflects a concern or an opening.